Real-world evidence (RWE) has been essential for the public health, pharma, and biotech response to the COVID-19 pandemic. In a new interview with Med Ad News, Matthew W. Reynolds, IQVIA’s vice president of scientific affairs and real world solutions, speaks about the use of RWE in studying COVID-19 breakthrough infections to prepare for the next outbreak.
According to Pharma Live, “Leveraging person-generated health data (PGHD) provides further detail into the impact of COVID-19 infection and associated vaccinations and is an additional level of information that is not available in traditional RWD sources (e.g., medical insurance claims or electronic health records [EHR]). The incorporation of PGHD allows patients to add their voice to highlight key information like the presence of specific COVID-19 symptoms and their severity, vaccine side effects and the impact on their quality of life. PGHD provides insight into what happens between medical visits, which is not normally or easily recorded in traditional RWD sources. Having this level of detail into the presence and severity of COVID-19 symptoms alone makes the inclusion of PGHD a necessity to conduct a high quality COVID-19 study.”
To read more, click here.
(Source: Pharma Live, November 29th, 2022)
